The Search for Disease-Modifying Therapies in Pulmonary Hypertension
Authors:
- 17 February 2019
- journal article
- review article
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 24 (4) , 334-354
Abstract
Pulmonary hypertension (PH) and its severe subtype pulmonary arterial hypertension (PAH) encompass a set of multifactorial diseases defined by sustained elevation of pulmonary arterial pressure and pulmonary vascular resistance leading to right ventricular failure and subsequent death. Pulmonary hypertension is characterized by vascular remodeling in association with smooth muscle cell proliferation of the arterioles, medial thickening, and plexiform lesion formation. Despite our recent advances in understanding its pathogenesis and related therapeutic discoveries, PH still remains a progressive disease without a cure. Nevertheless, development of drugs that specifically target molecular pathways involved in disease pathogenesis has led to improvement in life quality and clinical outcomes in patients with PAH. There are presently more than 12 Food and Drug Administration–approved vasodilator drugs in the United States for the treatment of PAH; however, mortality with contemporary therapies remains high. More recently, there have been exuberant efforts to develop new pharmacologic therapies that target the fundamental origins of PH and thus could represent disease-modifying opportunities. This review aims to summarize recent developments on key signaling pathways and molecular targets that drive PH disease progression, with emphasis on new therapeutic options under development.Keywords
Funding Information
- American Heart Association (18EIA33900027)
This publication has 233 references indexed in Scilit:
- Tyrosine Phosphorylation of Mitochondrial Pyruvate Dehydrogenase Kinase 1 Is Important for Cancer MetabolismMolecular Cell, 2011
- Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycleJournal of Molecular Medicine, 2011
- Covalent Peroxisome Proliferator-activated Receptor γ Adduction by Nitro-fatty AcidsJournal of Biological Chemistry, 2010
- Active NF-E2-related Factor (Nrf2) Contributes to Keep Endothelial NO Synthase (eNOS) in the Coupled StateJournal of Biological Chemistry, 2009
- MicroRNA-210 Controls Mitochondrial Metabolism during Hypoxia by Repressing the Iron-Sulfur Cluster Assembly Proteins ISCU1/2Cell Metabolism, 2009
- Synergistic Induction of Endothelin-1 by Tumor Necrosis Factor α and Interferon γ Is due to Enhanced NF-κB Binding and Histone Acetylation at Specific κB SitesJournal of Biological Chemistry, 2009
- Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertensionBritish Journal of Pharmacology, 2008
- Pathogenic mechanisms of pulmonary arterial hypertensionJournal of Molecular and Cellular Cardiology, 2008
- The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targetedProceedings of the National Academy of Sciences, 2007
- Nuclear factor-κB in cancer development and progressionNature, 2006